辅舒酮气雾剂联合孟鲁司特治疗支气管哮喘的疗效研究

目的：探讨辅舒酮气雾剂联合孟鲁司特治疗支气管哮喘的临床疗效；方法选择60例支气管哮喘患者随机分为两组，对照组和治疗组各30例，对照组予吸氧、抗炎、扩张支气管、全身糖皮质激素等常规基础治疗，治疗组在对照组的基础上吸入辅舒酮气雾剂联合口服孟鲁司特咀嚼片治疗，14天为一个疗程，一个疗程后比较两组患者的临床疗效、肺功能变化。结果治疗组临床总有效率为90%，高于对照组总有效率66.7%，两组疗效经Ridit分析，治疗组明显优于对照组（U=2.2733，p〈0.05），治疗期间两组均未出现明显不良反应。结论在常规治疗的基础上吸入辅舒酮气雾剂联合孟鲁司特治疗支气管哮喘方法疗效佳，值得在临床上广泛推广。

Clinical research of flixotide aerosol,montelukast in the treatment of bronchial asthma

Objective To investigate the clinical efficacy of the treatment with flixotide aerosol combination montelukast for Bronchial Asthma. Methods 60 patients with Bronchial Asthma were randomly divided into 2 groups, control group ＆amp; treatment group each 30 cases. Control group used conventional basic treatment, like oxygen, anti-inflammatory, bronchial expansion, and the systemic glucocorticoid treatment, and treatment group was also in the conventional way, moreover, plus the treatment of flixotide aerosol and oral montelukast chewable tablets. 14 days for a course of treatment, after a course of treatment, the two groups were compared in the efficacy and lung function changes. Results The total effective rate in the treatment group was 90%, higher than that of the control group total effectiveness 66.7%, two groups of curative effect by Ridit analysis, the treatment group was significantly better than the control group （U=2.2733, p〈0.05）, treatment during the two groups had no obvious adverse reaction. Conclusion It is much better to use the conventional treatment then plus the treatment of flixotide aerosol and montelukast for Bronchial Asthma, thus it is worth promoting in clinical.